Clinical Observation on Tianmeng Lingjiao Formula（天礞羚角方） as an Adjunctive Therapy for Paroxysmal Atrial Fibrillation with Phlegm-Heat Harassing the Interior Syndrome
10.13288/j.11-2166/r.2026.20.009
- VernacularTitle:天礞羚角方辅助治疗痰热内扰证阵发性房颤54例临床观察
- Author:
Jiafan CHEN
1
;
Chenglin DUAN
2
;
Yihang DU
1
;
Lianfen QI
1
;
Xinjue SHAN
2
;
Jiaqi LI
1
;
Wenjing ZHANG
1
;
Tao CHENG
3
;
Bochao JIA
2
;
Zizhen CHEN
1
;
Jingjing SHI
1
;
Yuguang CHU
1
;
Yuwen SUN
1
;
Yuanhui HU
1
Author Information
1. Guang'anmen Hospital，China Academy of Chinese Medical Sciences，Beijing，100053
2. Beijing University of Chinese Medicine
3. The First Medical Center of PLA General Hospital
- Publication Type:Journal Article
- Keywords:
paroxysmal atrial fibrillation;
phlegm-heat harassing the interior syndrome;
atrial fibrillation burden;
Tianmeng Lingjiao Formula（天礞羚角方）
- From:
Journal of Traditional Chinese Medicine
2026;67(20):2195-2201
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo observe the clinical efficacy and safety of Tianmeng Lingjiao Formula（天礞羚角方， TLF） as an adjunctive therapy for paroxysmal atrial fibrillation （PAF） with phlegm-heat harassing the interior syndrome. MethodsNinety patients with PAF and phlegm-heat harassing the interior syndrome were enrolled and randomly assigned in a 2∶1 ratio to test group （60 cases） and control group （30 cases）. The control group received conventional western medicine， while the test group received TLF in addition to the conventional treatment， with one dose administered daily. The treatment course for both groups was 4 weeks. The efficacy of traditional Chinese medicine （TCM） syndrome and the rate of atrial fibrillation （AF） conversion were compared between groups. Assessments included AF burden， frequency and duration of AF episodes， TCM syndrome scores， and European Heart Rhythm Association （EHRA） AF symptom classification before and after treatment. Safety indicators such as blood routine， urine routine， stool routine， liver function， kidney function， and electrolytes were also monitored. Adverse events were recorded. ResultsA total of 82 patients completed the study （54 in the test group and 28 in the control group）. After treatment， AF burden， the frequency and duration of AF episodes， and TCM syndrome scores were significantly reduced in both groups， and the test group showed lower indicators than the control group （P＜0.01 or P＜0.05）. The AF conversion rate was 25.93% （14/54） in the test group， significantly higher than 3.57% （1/28） in the control group （P＜0.05）. The total effective rate for TCM syndrome efficacy was 83.33% （45/54） in the test group， which was significantly higher than 67.86% （19/28） in the control group （P＜0.05）. After treatment， the EHRA atrial fibrillation symptom severity in the test group showed significant improvement， and the improvement in atrial fibrillation symptoms was superior to that in the control group （P＜0.01or P＜0.05）. No significant abnormalities were observed in safety indicators， and no adverse events occurred during the trial. ConclusionTLF as an adjunctive therapy can reduce AF burden， enhance the conversion rate of AF， decrease the frequency and duration of episodes， and improve clinical symptoms in patients with paroxysmal atrial fibrillation presenting with phlegm-heat harassing the interior syndrome， with a favorable safety profile.
